BUZZ-Kyverna shares surge as cell therapy shows durable efficacy in rare neurological diseases

September 24 - ** Shares of biotechnology company Kyverna Therapeutics (KYTX.O) rose 6.1% in premarket trading to $7.50

** The company said its experimental cell therapy, miv-cel, produces effects in the treatment of stiff-person syndrome—a rare disease causing severe muscle stiffness and spasms—that can last for one year

** 95% of patients who achieved a significant improvement in mobility maintained this effect after one year; 92% of patients no longer required ongoing chronic immunotherapy

** Reportedly, among patients who needed walking aids before treatment, 67% no longer needed assistive devices

** The company remains on track to complete its rolling submission for miv-cel approval in the US by the fourth quarter of 2026

** Independent follow-up data for myasthenia gravis—a disease characterized by muscle weakness—show efficacy may last up to 1.5 years; final patient recruitment for this clinical trial is expected to be completed by mid-2027

** As of the previous trading day’s close, the stock was down about 25% year-to-date

(To assist non-native English speakers, Reuters has automated the translation of its report into several other languages. Because automated translation may contain errors or may not include the necessary context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for the convenience of readers. Reuters assumes no responsibility for any harm or loss caused by the use of the automated translation feature.)